Hirata, Koichi
Sano, Hiromi
Kondo, Hiroyuki
Shibasaki, Yoshiyuki
Koga, Nobuyuki
Funding for this research was provided by:
Otsuka Pharmaceutical
Article History
Received: 26 April 2022
Accepted: 15 February 2023
First Online: 21 February 2023
Declarations
:
: As this survey used only anonymized data and the authors, data analysts, and any parties involved in the study including Otsuka Pharmaceutical Co., Ltd. and Clinical Study Support Inc. did not possess or receive correspondence sheets, it was impossible for those involved to identify individuals included in the study. As the study using anonymized data is outside the scope of the national guidelines “Ethical Guidelines for Medical and Health Research Involving Human Subjects”, the ethical committee review and individual-level consent were not required. However, the study protocol was approved by the ethics committee of the Research Institute of Healthcare Data Science (approval No.: RI2020012). Additionally, the study including the survey was performed in accordance with the Declaration of Helsinki (revised October 2013) by the World Medical Association and the Ethical Guidelines for Medical Research Involving Human Subjects.
: Not applicable.
: HS, HK, YS, and NK are employees of Otsuka Pharmaceutical Co., Ltd. (Japan). KH received consulting fees from Otsuka Pharmaceutical Co., Ltd., during the conduct of the study; consulting fees from Otsuka Pharmaceutical Co., Ltd., Eli Lilly Japan K.K., Amgen Astellas BioPharma K.K., and Lundbeck Japan K.K.; lecture Honoraria from Otsuka Pharmaceutical Co., Ltd., Eli Lilly Japan K.K., Eisai Co., Pfizer Japan, Daiichi Sankyo Co., Ltd., MSD Co., Ltd., Amgen Astellas BioPharma K.K., Ltd., and Lundbeck Japan K.K., outside the submitted work.